glp 1 comorbidities Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society GLP-1 Agonists For Obesity In
Description
In the latest trials, participants had an average BMI of 37 and were mostly women with a median age of 50
By reducing hunger and promoting feelings of fullness, GLP-1 injections make it easier to stick to a balanced diet, ultimately leading to a reduction in calorie intake
doi: 10.1111/hepr.12837
Some patients notice early changes over time, while others experience more gradual progress with continued provider guidance
The MHRA has issued drug safety updates relevant to renal safety
